706 related articles for article (PubMed ID: 36414938)
1. Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis.
Pai H; Ndjeka N; Mbuagbaw L; Kaniga K; Birmingham E; Mao G; Alquier L; Davis K; Bodard A; Williams A; Van Tongel M; Thoret-Bauchet F; Omar SV; Bakare N
BMC Infect Dis; 2022 Nov; 22(1):870. PubMed ID: 36414938
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of bedaquiline-containing regimens for treatment on patients with refractory RR/MDR/XDR-tuberculosis: a retrospective cohort study in East China.
Zhang SJ; Yang Y; Sun WW; Zhang ZS; Xiao HP; Li YP; Zhang ZM; Fan L
BMC Infect Dis; 2022 Aug; 22(1):715. PubMed ID: 36038829
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
4. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
5. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
[TBL] [Abstract][Full Text] [Related]
6. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.
Pym AS; Diacon AH; Tang SJ; Conradie F; Danilovits M; Chuchottaworn C; Vasilyeva I; Andries K; Bakare N; De Marez T; Haxaire-Theeuwes M; Lounis N; Meyvisch P; Van Baelen B; van Heeswijk RP; Dannemann B;
Eur Respir J; 2016 Feb; 47(2):564-74. PubMed ID: 26647431
[TBL] [Abstract][Full Text] [Related]
7. [Study on the resistance of rifampicin-resistant Mycobacterium tuberculosis to anti-tuberculosis drugs in group A].
Dai XW; Li CY; Wang NH; Chen SS; Tian LL; Zhao YF; Tao LY; Yang XY; Ding BC; He XX
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1110-1117. PubMed ID: 37914422
[No Abstract] [Full Text] [Related]
8. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
[TBL] [Abstract][Full Text] [Related]
9. High fluoroquinolone resistance proportions among multidrug-resistant tuberculosis driven by dominant L2 Mycobacterium tuberculosis clones in the Mumbai Metropolitan Region.
Dreyer V; Mandal A; Dev P; Merker M; Barilar I; Utpatel C; Nilgiriwala K; Rodrigues C; Crook DW; ; Rasigade JP; Wirth T; Mistry N; Niemann S
Genome Med; 2022 Aug; 14(1):95. PubMed ID: 35989319
[TBL] [Abstract][Full Text] [Related]
10. Assessment of epidemiological and genetic characteristics and clinical outcomes of resistance to bedaquiline in patients treated for rifampicin-resistant tuberculosis: a cross-sectional and longitudinal study.
Ismail NA; Omar SV; Moultrie H; Bhyat Z; Conradie F; Enwerem M; Ferreira H; Hughes J; Joseph L; Kock Y; Letsaolo V; Maartens G; Meintjes G; Ngcamu D; Okozi N; Padanilam X; Reuter A; Romero R; Schaaf S; Te Riele J; Variava E; van der Meulen M; Ismail F; Ndjeka N
Lancet Infect Dis; 2022 Apr; 22(4):496-506. PubMed ID: 34780706
[TBL] [Abstract][Full Text] [Related]
11. A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea.
Shim TS; Pai H; Mok J; Lee SH; Kwon YS; Choi JC; Park J; Birmingham E; Mao G; Alquier L; Davis K; Thoret-Bauchet F; Kim JH; Kim H; Bakare N
BMC Infect Dis; 2023 Jan; 23(1):15. PubMed ID: 36624432
[TBL] [Abstract][Full Text] [Related]
12. Emergence of bedaquiline-resistant tuberculosis and of multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains with rpoB Ile491Phe mutation not detected by Xpert MTB/RIF in Mozambique: a retrospective observational study.
Barilar I; Fernando T; Utpatel C; Abujate C; Madeira CM; José B; Mutaquiha C; Kranzer K; Niemann T; Ismael N; de Araujo L; Wirth T; Niemann S; Viegas S
Lancet Infect Dis; 2024 Mar; 24(3):297-307. PubMed ID: 37956677
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
Pitso L; Potgieter S; Van der Spoel van Dijk A
S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
[TBL] [Abstract][Full Text] [Related]
14. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
[TBL] [Abstract][Full Text] [Related]
15. Bedaquiline Drug Resistance Emergence Assessment in Multidrug-Resistant Tuberculosis (MDR-TB): a 5-Year Prospective
Kaniga K; Hasan R; Jou R; Vasiliauskienė E; Chuchottaworn C; Ismail N; Metchock B; Miliauskas S; Viet Nhung N; Rodrigues C; Shin S; Simsek H; Smithtikarn S; Ngoc ALT; Boonyasopun J; Kazi M; Kim S; Kamolwat P; Musteikiene G; Sacopon CA; Tahseen S; Vasiliauskaitė L; Wu MH; Vally Omar S
J Clin Microbiol; 2022 Jan; 60(1):e0291920. PubMed ID: 34705538
[TBL] [Abstract][Full Text] [Related]
16. Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006-2019.
Kherabi Y; Fréchet-Jachym M; Rioux C; Yazdanpanah Y; Méchaï F; Pourcher V; Robert J; Guglielmetti L;
Emerg Infect Dis; 2022 Sep; 28(9):1796-1804. PubMed ID: 35997386
[TBL] [Abstract][Full Text] [Related]
17. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study.
Ndjeka N; Campbell JR; Meintjes G; Maartens G; Schaaf HS; Hughes J; Padanilam X; Reuter A; Romero R; Ismail F; Enwerem M; Ferreira H; Conradie F; Naidoo K; Menzies D
Lancet Infect Dis; 2022 Jul; 22(7):1042-1051. PubMed ID: 35512718
[TBL] [Abstract][Full Text] [Related]
18. Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study.
Derendinger B; Dippenaar A; de Vos M; Huo S; Alberts R; Tadokera R; Limberis J; Sirgel F; Dolby T; Spies C; Reuter A; Folkerts M; Allender C; Lemmer D; Van Rie A; Gagneux S; Rigouts L; Te Riele J; Dheda K; Engelthaler DM; Warren R; Metcalfe J; Cox H; Theron G
Lancet Microbe; 2023 Dec; 4(12):e972-e982. PubMed ID: 37931638
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis.
Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N; Kotrikadze T; Hayrapetyan A; Avaliani Z; Schünemann HJ; Lienhardt C
Emerg Infect Dis; 2019 May; 25(5):936-943. PubMed ID: 31002070
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.
Borisov SE; Dheda K; Enwerem M; Romero Leyet R; D'Ambrosio L; Centis R; Sotgiu G; Tiberi S; Alffenaar JW; Maryandyshev A; Belilovski E; Ganatra S; Skrahina A; Akkerman O; Aleksa A; Amale R; Artsukevich J; Bruchfeld J; Caminero JA; Carpena Martinez I; Codecasa L; Dalcolmo M; Denholm J; Douglas P; Duarte R; Esmail A; Fadul M; Filippov A; Davies Forsman L; Gaga M; Garcia-Fuertes JA; García-García JM; Gualano G; Jonsson J; Kunst H; Lau JS; Lazaro Mastrapa B; Teran Troya JL; Manga S; Manika K; González Montaner P; Mullerpattan J; Oelofse S; Ortelli M; Palmero DJ; Palmieri F; Papalia A; Papavasileiou A; Payen MC; Pontali E; Robalo Cordeiro C; Saderi L; Sadutshang TD; Sanukevich T; Solodovnikova V; Spanevello A; Topgyal S; Toscanini F; Tramontana AR; Udwadia ZF; Viggiani P; White V; Zumla A; Migliori GB
Eur Respir J; 2017 May; 49(5):. PubMed ID: 28529205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
